Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50861 |
Name | colorectal adenocarcinoma |
Definition | A colorectal carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer colorectal carcinoma colorectal adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600E | DEL-22379 | colorectal adenocarcinoma | sensitive | detail... |
FGFR2 amp | RO4987655 | colorectal adenocarcinoma | decreased response | detail... |
FGFR2 amp | RO5126766 | colorectal adenocarcinoma | predicted - sensitive | detail... |
FGFR2 amp | Selumetinib | colorectal adenocarcinoma | no benefit | detail... |
CTNNB1 S45F | NTRC 0066-0 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | NTRC 0066-0 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | Mps-BAY2b | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | Mps-BAY2b | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | NMS-P715 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | NMS-P715 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45del | BAY1161909 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | BAY1161909 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | BAY1217389 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | BAY1217389 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | Mps1-IN-1 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | Mps1-IN-1 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S33Y | MPI-0479605 | colorectal adenocarcinoma | predicted - sensitive | detail... |
CTNNB1 S45F | MPI-0479605 | colorectal adenocarcinoma | predicted - sensitive | detail... |
ARID1B inact mut | unspecified immune checkpoint inhibitor | colorectal adenocarcinoma | unknown | detail... |
ARID2 inact mut | unspecified immune checkpoint inhibitor | colorectal adenocarcinoma | unknown | detail... |
PBRM1 inact mut | unspecified immune checkpoint inhibitor | colorectal adenocarcinoma | unknown | detail... |
SMARCA4 inact mut | unspecified immune checkpoint inhibitor | colorectal adenocarcinoma | unknown | detail... |
SMARCB1 inact mut | unspecified immune checkpoint inhibitor | colorectal adenocarcinoma | unknown | detail... |
BRAF V600E | ASTX029 | colorectal adenocarcinoma | sensitive | detail... |
ATM I1294Nfs*8 ATM E2977Rfs*2 | Irinotecan + Olaparib | colorectal adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | RO5126766 | colorectal adenocarcinoma | sensitive | detail... |
FGFR2 amp | Lirafugratinib | colorectal adenocarcinoma | sensitive | detail... |
PIK3CA E545G | Palbociclib + PD-0325901 | colorectal adenocarcinoma | sensitive | detail... |
PIK3CA E545G | Gedatolisib + Palbociclib | colorectal adenocarcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00113763 | Phase III | Panitumumab | Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer | Completed | 0 | |
NCT00408772 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin | Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery | Withdrawn | USA | 0 |
NCT00842257 | Phase II | Panitumumab | Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer | Completed | USA | 0 |
NCT01061515 | Phase I | Capecitabine Bevacizumab Oxaliplatin | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT01079780 | Phase II | Cetuximab + Irinotecan + Ramucirumab Cetuximab + Irinotecan | Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy | Completed | USA | 0 |
NCT01420874 | Phase I | EGFRBi-armed autologous activated T cells Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) | Completed | USA | 0 |
NCT01442935 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | Completed | FRA | 0 |
NCT01471353 | Phase II | Capecitabine + Sorafenib | Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01571284 | Phase III | Aflibercept + Fluorouracil + Irinotecan + Leucovorin | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | Completed | USA | TUR | SWE | NOR | NLD | LBN | ITA | ISR | IRL | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | 5 |
NCT01622543 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Pelareorep | Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer | Completed | CAN | 0 |
NCT01642342 | Phase I | sEphB4-HSA | Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors | Terminated | USA | 0 |
NCT01652196 | Phase II | Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | Unknown status | USA | 0 |
NCT01652482 | Phase II | Cetuximab Duligotuzumab Fluorouracil + Irinotecan + Leucovorin | A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | ROU | NZL | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 0 |
NCT01802320 | Phase II | MK2206 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT01814501 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | Unknown status | USA | 0 |
NCT01851369 | Phase Ib/II | Temozolomide + TRC102 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01949194 | Phase II | Regorafenib | Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers | Unknown status | CAN | 0 |
NCT02023333 | Phase II | Regorafenib | Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02116894 | Phase I | Ascrinvacumab + Regorafenib | Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer | Completed | USA | 0 |
NCT02149108 | Phase III | Nintedanib | Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer | Completed | USA | TUR | SWE | POL | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | ARG | 7 |
NCT02235324 | Phase II | Aflibercept + Fluorouracil + Leucovorin Aflibercept | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | Withdrawn | USA | 0 |
NCT02248805 | Phase I | MGD007 | Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma | Completed | USA | 0 |
NCT02292758 | Phase II | Bevacizumab + Cetuximab + Irinotecan Cetuximab + Irinotecan | Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02368886 | Phase II | Clobetasol + Regorafenib | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02375672 | Phase II | Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02413853 | Phase II | Bevacizumab PRI-724 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer | Withdrawn | USA | 0 |
NCT02466009 | Phase II | Regorafenib | Regorafenib in Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Completed | USA | POL | ESP | DEU | CHE | BEL | AUT | AUS | 1 |
NCT02574663 | Phase I | Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02602327 | Phase I | Trifluridine-tipiracil hydrochloride | Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases | Completed | USA | 0 |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02651415 | Phase II | Perindopril + Regorafenib | Phase II Study of Perindopril and Regorafenib in mCRC | Completed | CAN | 0 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Unknown status | USA | 1 |
NCT02780700 | Phase II | Capecitabine + Nintedanib Nintedanib | Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2] | Terminated | USA | 0 |
NCT02835833 | Phase I | Bevacizumab + Nintedanib | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | Completed | USA | 0 |
NCT02860546 | Phase II | Nivolumab + Trifluridine-tipiracil hydrochloride | A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | Completed | USA | 0 |
NCT02876224 | Phase I | Atezolizumab + Bevacizumab + Cobimetinib | Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | Completed | USA | ESP | 0 |
NCT02885753 | Phase III | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR) | Recruiting | FRA | CHE | 0 |
NCT02908451 | Phase I | AbGn-107 | A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer | Terminated | USA | 1 |
NCT03007407 | Phase II | Tremelimumab Durvalumab | Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | Completed | USA | 0 |
NCT03069950 | Phase II | Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver | Withdrawn | USA | 0 |
NCT03081494 | Phase I | Regorafenib + Spartalizumab | Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Completed | NLD | ITA | ISR | ESP | CAN | AUS | 2 |
NCT03087071 | Phase II | Panitumumab Panitumumab + Trametinib | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Completed | USA | 0 |
NCT03104439 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Recruiting | USA | 0 |
NCT03117972 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine | Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (CLavSyn) | Active, not recruiting | FRA | 0 |
NCT03186326 | Phase II | Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Avelumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) | Unknown status | FRA | 0 |
NCT03192345 | Phase I | Cemiplimab + SAR439459 SAR439459 | A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | EST | ESP | DEU | CAN | BEL | AUS | 2 |
NCT03258398 | Phase II | Avelumab + Tomivosertib Tomivosertib | A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer | Completed | USA | 0 |
NCT03277209 | Phase I | Plerixafor | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas | Terminated | USA | GBR | 0 |
NCT03300609 | Phase III | Capecitabine Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Fluorouracil + Leucovorin + Panitumumab | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | Terminated | USA | 0 |
NCT03332498 | Phase Ib/II | Ibrutinib + Pembrolizumab | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | Completed | USA | 0 |
NCT03337087 | Phase Ib/II | Fluorouracil + Leucovorin + Liposomal irinotecan + Rucaparib | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | Active, not recruiting | USA | 0 |
NCT03366155 | Phase II | Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | Recruiting | USA | 0 |
NCT03368963 | Phase Ib/II | Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Recruiting | USA | 0 |
NCT03373188 | Phase I | Nivolumab + Pepinemab Ipilimumab + Pepinemab Pepinemab | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | Completed | USA | 0 |
NCT03376659 | Phase Ib/II | Capecitabine + CV301 + Durvalumab Bevacizumab + Capecitabine + CV301 + Durvalumab | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | Terminated | USA | 0 |
NCT03377361 | Phase Ib/II | Regorafenib Ipilimumab + Nivolumab + Trametinib Nivolumab + Trametinib | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9) | Active, not recruiting | USA | ITA | ESP | DEU | CZE | CAN | BEL | AUS | ARG | 1 |
NCT03384940 | Phase II | Trastuzumab deruxtecan | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | Completed | USA | ITA | GBR | ESP | 1 |
NCT03396926 | Phase II | Bevacizumab + Capecitabine + Pembrolizumab | Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03436563 | Phase Ib/II | Bintrafusp alfa | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | Active, not recruiting | USA | 0 |
NCT03442569 | Phase II | Ipilimumab + Nivolumab + Panitumumab | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC | Active, not recruiting | USA | 0 |
NCT03475004 | Phase II | Bevacizumab + Binimetinib + Pembrolizumab | Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | Completed | USA | 0 |
NCT03539822 | Phase I | Cabozantinib + Durvalumab | Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) | Active, not recruiting | USA | 0 |
NCT03542877 | Phase II | Cabozantinib | Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03576963 | Phase Ib/II | Guadecitabine + Nivolumab | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Withdrawn | USA | 0 |
NCT03597581 | Phase I | RGX202 Fluorouracil + Irinotecan + Leucovorin + RGX202 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + RGX202 | A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | Recruiting | USA | 0 |
NCT03608046 | Phase II | Avelumab + Cetuximab + Irinotecan | Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI) | Unknown status | BEL | 0 |
NCT03610490 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT03626922 | Phase I | Folic Acid Cyanocobalamin Oxaliplatin + Pembrolizumab + Pemetrexed Disodium Dexamethasone Pembrolizumab + Pemetrexed Disodium | Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients | Unknown status | USA | 0 |
NCT03642067 | Phase II | Nivolumab + Relatlimab | Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Active, not recruiting | USA | AUS | 4 |
NCT03712943 | Phase I | Nivolumab + Regorafenib | Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer | Completed | USA | 0 |
NCT03715933 | Phase I | INBRX-109 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Recruiting | USA | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03750786 | Phase III | Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT) | Completed | USA | SWE | GRC | FRA | ESP | DEU | CAN | AUT | AUS | 1 |
NCT03800602 | Phase II | Metformin + Nivolumab | Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer | Completed | USA | 0 |
NCT03828227 | Phase III | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine | Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters (COLAGE) | Active, not recruiting | FRA | 0 |
NCT03874026 | Phase II | Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA) | Recruiting | ITA | 0 |
NCT04014530 | Phase Ib/II | Pembrolizumab + PTC124 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study (ATAPEMBRO) | Recruiting | NLD | 0 |
NCT04054752 | Phase I | NT-I7 | Vaccine Response With NT-I7 | Withdrawn | USA | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04094688 | Phase III | Bevacizumab + Cholecalciferol + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Cholecalciferol + Fluorouracil + Irinotecan + Leucovorin | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer (SOLARIS) | Active, not recruiting | USA | 1 |
NCT04111172 | Phase II | Ad5.F35-hGCC-PADRE | Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies | Suspended | USA | 0 |
NCT04117945 | Phase II | Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04119830 | Phase II | Pembrolizumab + Rintatolimod | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer | Withdrawn | USA | 0 |
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Completed | USA | FRA | ESP | DEU | BEL | 3 |
NCT04166435 | Phase II | Olaparib + Temozolomide | TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer | Completed | USA | 0 |
NCT04171141 | Phase I | PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | Terminated | USA | AUS | 1 |
NCT04188145 | Phase III | Capecitabine Fluorouracil + Leucovorin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine | A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer (BEVAMAINT) | Recruiting | FRA | 0 |
NCT04214418 | Phase Ib/II | Atezolizumab + Cobimetinib + Hydroxychloroquine | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) | Active, not recruiting | USA | 0 |
NCT04262687 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin + Pembrolizumab | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (POCHI) | Recruiting | FRA | 0 |
NCT04310176 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil Bevacizumab + Fluorouracil + Valproic acid Bevacizumab + Capecitabine + Valproic acid Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Valproic acid Bevacizumab + Capecitabine + Oxaliplatin + Valproic acid | Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (REVOLUTION) | Recruiting | ITA | 0 |
NCT04322539 | Phase III | Fruquintinib | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer (FRESCO-2) | Active, not recruiting | USA | POL | ITA | HUN | GBR | FRA | EST | ESP | DEU | CZE | BEL | AUT | AUS | 1 |
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT04456699 | Phase III | Bevacizumab + Olaparib Bevacizumab + Fluorouracil Olaparib | Efficacy and Safety of Olaparib, Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU) | Completed | USA | TUR | LVA | LTU | HUN | FRA | ESP | DEU | CAN | BEL | AUS | 7 |
NCT04457284 | Phase II | Cisplatin + Nivolumab + Temozolomide | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04474470 | Phase Ib/II | Cetuximab + NT219 NT219 | A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer | Completed | USA | ISR | 0 |
NCT04491955 | Phase II | Bintrafusp alfa + CV301 + NHS-IL12 + Nogapendekin alfa inbakicept Bintrafusp alfa + CV301 + Nogapendekin alfa inbakicept | Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers | Completed | USA | 0 |
NCT04513951 | Phase II | Avelumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC) | Active, not recruiting | ITA | 0 |
NCT04557449 | Phase I | Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) | Recruiting | USA | SVK | GBR | CZE | ARG | 3 |
NCT04575922 | Phase II | Ipilimumab + Nivolumab | Nivolumab+Ipilimumab+RT in MSS mCRC | Unknown status | USA | 0 |
NCT04660812 | Phase Ib/II | AB680 + Etrumadenant + Zimberelimab Regorafenib Bevacizumab + Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer. | Active, not recruiting | USA | ITA | GBR | FRA | ESP | 1 |
NCT04689347 | Phase I | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Temozolomide | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | Unknown status | ITA | 0 |
NCT04729322 | Phase I | Fecal microbiota + Nivolumab Fecal microbiota + Pembrolizumab | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | Active, not recruiting | USA | 0 |
NCT04730544 | Phase II | Ipilimumab + Nivolumab | Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) | Recruiting | FRA | 0 |
NCT04731467 | Phase Ib/II | CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | Active, not recruiting | USA | ISR | ESP | 0 |
NCT04744831 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02) | Completed | USA | ITA | GBR | FRA | ESP | BEL | AUS | 3 |
NCT04776148 | Phase III | Regorafenib Trifluridine-tipiracil hydrochloride Lenvatinib + Pembrolizumab | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | Completed | USA | TUR | ISR | GBR | ESP | DNK | DEU | CAN | AUS | ARG | 5 |
NCT04776655 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb) | Unknown status | ITA | 0 |
NCT04853043 | Phase II | Cetuximab | Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT04868773 | Phase I | Cabozantinib + Trifluridine-tipiracil hydrochloride | Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy | Active, not recruiting | USA | 0 |
NCT04873895 | Phase I | Axitinib + Hydroxychloroquine | TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC) (TACE-Ax-HCQ) | Terminated | USA | 0 |
NCT04895722 | Phase II | MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LTU | ITA | HUN | GRC | GBR | FRA | EST | ESP | DNK | DEU | CAN | BEL | 5 |
NCT04952753 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3) | Active, not recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUS | 5 |
NCT04963283 | Phase II | Cabozantinib + Nivolumab | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05064059 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride MK-4280A | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | Active, not recruiting | USA | TUR | NOR | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 9 |
NCT05067283 | Phase I | MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Recruiting | USA | TUR | POL | NZL | ITA | ISR | ESP | DNK | CHE | CAN | AUS | 7 |
NCT05075564 | Phase I | ES002023 | A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | Unknown status | USA | 0 |
NCT05087992 | Phase I | Bevacizumab + BI 905711 + Fluorouracil + Irinotecan + Leucovorin BI 905711 + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | Completed | USA | FRA | BEL | 2 |
NCT05121038 | Phase Ib/II | CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin CEND-1 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab (CENDIFOX) | Recruiting | USA | 0 |
NCT05130060 | Phase I | PolyPEPI1018 + Trifluridine-tipiracil hydrochloride | A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT05198934 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride Panitumumab + Sotorasib | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak300) | Active, not recruiting | USA | ITA | GRC | GBR | FRA | ESP | DEU | AUS | 4 |
NCT05200442 | Phase Ib/II | Cetuximab + RO5126766 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Recruiting | USA | 0 |
NCT05221320 | Phase II | Hydroxychloroquine + Ulixertinib | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Terminated | USA | 0 |
NCT05223673 | Phase III | Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR) | Terminated | USA | HUN | FIN | DNK | BEL | 1 |
NCT05253651 | Phase III | Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) | Recruiting | USA | SVK | POL | NOR | NLD | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT05286814 | Phase II | Fluorouracil + Leucovorin + NHS-IL12 + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NHS-IL12 | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT05291156 | Phase II | Cetuximab Avelumab + Cetuximab | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | Recruiting | ITA | 0 |
NCT05310643 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy (NIPIRESCUE) | Recruiting | FRA | 0 |
NCT05312398 | Phase II | Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin | CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen | Active, not recruiting | ITA | 0 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT05328908 | Phase III | Regorafenib + Trifluridine-tipiracil hydrochloride Nivolumab and relatlimab-rmbw | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) | Active, not recruiting | USA | SWE | POL | NLD | ITA | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | ARG | 7 |
NCT05330429 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin | Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC) | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT05382741 | Phase II | Durvalumab + Regorafenib | Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial (VIVA) | Recruiting | ITA | 0 |
NCT05429762 | Phase I | SAR408701 | Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT) | Terminated | USA | TUR | FRA | ESP | BEL | 0 |
NCT05482516 | Phase III | Atezolizumab + Bevacizumab | Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) | Recruiting | USA | 0 |
NCT05504252 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Nivolumab | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin (METIMMOX-2) | Recruiting | NOR | 0 |
NCT05576077 | Phase I | Pembrolizumab + TBio-4101 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) | Recruiting | USA | CAN | 0 |
NCT05589597 | Phase Ib/II | EO4010 + Nivolumab EO4010 | EO4010 in Previously Treated Metastatic Colorectal Carcinoma (AUDREY) | Active, not recruiting | USA | FRA | ESP | 0 |
NCT05608044 | Phase II | Balstilimab + Botensilimab Botensilimab | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Active, not recruiting | USA | ITA | FRA | ESP | BRA | BEL | 2 |
NCT05609370 | Phase Ib/II | Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab Bevacizumab + Fluorouracil + LBL-007 Bevacizumab + Fluorouracil Bevacizumab + Capecitabine + LBL-007 + Tislelizumab Bevacizumab + Capecitabine + LBL-007 | A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | Recruiting | USA | AUS | 2 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05631327 | Phase I | JZP341 | JZP341 Phase 1 Dose-Finding Study in Adult Participants With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05646797 | Phase I | ASP2074 | A Study of ASP2074 in Adults With Solid Tumors | Terminated | USA | 1 |
NCT05733611 | Phase II | Atezolizumab + Bevacizumab + RP2 Atezolizumab + Bevacizumab + RP3 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Active, not recruiting | USA | 0 |
NCT05743036 | Phase Ib/II | Cetuximab + Encorafenib + ZN-c3 | ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | Recruiting | USA | POL | ITA | HUN | ESP | DEU | AUS | 0 |
NCT05784688 | Phase Ib/II | Pembrolizumab + TU2218 | Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05848843 | Phase I | Adagrasib + Durvalumab | A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations | Withdrawn | USA | 0 |
NCT05854498 | Phase II | Bevacizumab + Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT05877599 | Phase I | NT-175 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Recruiting | USA | 0 |
NCT05909423 | Phase II | Influenza vaccine + Pembrolizumab | Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer (FLU-IMMUNE) | Not yet recruiting | DNK | 0 |
NCT05983367 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RGX202 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | Active, not recruiting | FRA | ESP | BEL | 0 |
NCT05985655 | Phase Ib/II | GTAEXS617 | Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) | Recruiting | GBR | BEL | 0 |
NCT06043713 | Phase I | Bendamustine FHA-11 KRAS G12V-TCR Cyclophosphamide + Fludarabine | Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations | Recruiting | USA | 0 |
NCT06102902 | Phase I | Cetuximab + Encorafenib + ZEN-3694 | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | Recruiting | USA | 0 |
NCT06178614 | Phase I | JNJ-87890387 | A Study of JNJ-87890387 for Advanced Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT06218914 | Phase I | NT-112 | A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | Recruiting | USA | 0 |
NCT06252649 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab + Sotorasib | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naive Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) | Recruiting | USA | TUR | BRA | AUS | ARG | 5 |
NCT06300463 | Phase II | Balstilimab + Botensilimab + GS-1423 Balstilimab + Botensilimab | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Recruiting | USA | 0 |
NCT06314997 | Phase II | Panitumumab | Dynamic Changes in Circulating Tumour Cells Protein Expression (Liquid-DRER2) | Recruiting | ITA | 0 |
NCT06445062 | Phase Ib/II | Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236 Gemcitabine + Nab-paclitaxel + RMC-6236 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + RMC-6236 Cetuximab + RMC-6236 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RMC-6236 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Recruiting | USA | 0 |
NCT06457997 | Phase I | PHN-010 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06529523 | Phase II | Tislelizumab | Tislelizumab in People With Colorectal Cancer | Recruiting | USA | 1 |
NCT06578559 | Phase II | Cetuximab + Encorafenib | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET) | Recruiting | ITA | 0 |
NCT06598371 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin + KSQ-004EX KSQ-004EX | A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06640166 | Phase II | Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin | Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. (ECLYPse) | Recruiting | ITA | 0 |
NCT06663319 | Phase I | JNJ-89402638 | A Study of JNJ-89402638 for Metastatic Colorectal Cancer | Recruiting | USA | 0 |